Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.